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The purpose of this study was to evaluate the impact of prosthetic replacement of the ocular surface
ecosystem (BostonSight PROSE, Boston Foundation for Sight, Needham, MA) treatment, utilizing customized
scleral devices, on visual acuity, visual function, and ocular surface changes in patients with ocular chronic
graft-versus-host disease (cGVHD). A retrospective analysis was performed on 79 eyes of 40 patients with
cGVHD referred to the University of Southern California department of ophthalmology between November
2009 and July 2013 for PROSE treatment. This analysis included an assessment of ocular symptoms and visual
function before and after treatment using the Ocular Surface Disease Index (OSDI) survey. Pre- and post-
treatment visual acuity and clinical data were also compared. Twenty-eight male patients and 12 female
patients were included in this study. The average age was 56.1 years (range, 27 to 74). Of the 79 eyes treated,
71 (90%) showed improved visual acuity with PROSE treatment. Fifty-seven eyes (72%) experienced a 2- or
greater line visual acuity improvement and 14 eyes (18%) experienced a 1-line improvement. Average loga-
rithm of the minimal angle of resolution improved from .49  .52 to .16  .44 (P < .0001), which correlates to
a Snellen score improvement of approximately 20/60 to 20/30. Sixty-six of 79 eyes (84%) showed decreased
corneal staining after treatment. All 9 eyes presenting with ﬁlamentary keratitis and 3 eyes with epithelial
defects demonstrated complete healing of the epithelial surface after PROSE ﬁtting. At post-treatment follow-
up, 8 patients had died and 3 stopped wearing their devices. Of the remaining 29 patients, average OSDI
scores improved from 72.6  20.1 to 21.1  14.9 (P < .0001). PROSE therapy, utilizing customized scleral
lenses, can reduce ocular symptoms, improve visual acuity, and improve ocular surface integrity or appear-
ance in patients with ocular cGVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) is a frequent and
serious complication of allogeneic hematopoietic stem cell
transplantation, affecting between 30% and 70% of HLA-
matched patients [1,2]. Pathogenically, the condition is
characterized by a donor T and B cellemediated response to
host tissue antigen in a variety of organs. Although patients
most commonly present with skin, mouth, or liver involve-
ment, gastrointestinal, musculoskeletal, respiratory, renal,
cardiac, and ocular symptoms may also occur [3,4].edgments on page 2184.
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ty for Blood and Marrow Transplantation.Ocular inﬂammation occurs in up to 50% to 80% of chronic
GVHD (cGVHD) patients and can affect any part of the eye
and adnexa, including the lacrimal glands, eyelids, conjunc-
tivae, meibomian glands, sclera, and cornea [5,6]. Patients
may present with ocular pain, burning, foreign body sensa-
tion, epiphora, blurry vision, and photophobia [5]. These
symptoms can signiﬁcantly limit a patient’s quality of life and
potentially lead to vision loss. Even in less severe cases, pa-
tients often struggle with routine tasks, such as reading,
watching television, or working on a computer, and they can
experience signiﬁcant discomfort in windy or dry environ-
ments [3].
Traditional treatment for ocular GVHD can involve sys-
temic and topical agents to either suppress inﬂammation or
lubricate the ocular surface. Additional options, such as
punctal occlusion, superﬁcial debridement of ﬁlamentary
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More recently, gas-permeable scleral lenses have emerged as
a treatment option for patients who do not have success with
conventional therapies [8,9].
The prosthetic replacement of the ocular surface
ecosystem (BostonSight PROSE, Boston Foundation for Sight,
Needham, MA) scleral lens, previously known as the Boston
Ocular Surface Prosthesis, is a highly customizable device
that sits on the sclera and vaults the corneal surface [10]. This
device is unique in that PROSE Design-to-Fit software (Bos-
ton Foundation for Sight), which optimizes the lens design
for each eye, is used directly by the ﬁtting clinician. All PROSE
devices, approved in 1994 by the Food and Drug Adminis-
tration for the treatment of corneal disorders [11], are
manufactured by the Boston Foundation for Sight in Need-
ham, MA. The device supplies constant lubrication to the
corneal surface while allowing tear exchange during blink-
ing. Compared with other scleral lens ﬁttings, PROSE treat-
ment is offered only at hospitals that have established
ophthalmology departments. This gives optometrists
providing PROSE services the ability to comanage chal-
lenging cases with a corneal specialist. In addition, all PROSE
clinicians must complete additional training at the Boston
Foundation for Sight before providing treatment. Given these
guidelines and the specialized computer software utilized,
PROSE devices are generally more costly than other lens
options and, therefore, have typically been reserved for pa-
tients who have not had success with other treatment mo-
dalities. To date, no head-to-head comparison of PROSE
treatment with other scleral lenses has been reported. The
proﬁle of a device is shown in Figure 1.
Prior studies have shown the safety and efﬁcacy of PROSE
treatment in patients with keratoconus, Stevens-Johnson
Syndrome, GVHD, severe dry eye syndrome, and post-
surgical irregular astigmatism [8,9,12]. In a retrospective
study of 33 patients with ocular GVHD, Jacobs and Rosenthal
showed symptom and quality of life improvements. In that
study, more than one half of patients surveyed after wearing
the device reported improvement in pain (52%), photophobia
(63%), and overall quality of life (73%) [13].
Our study expands upon these reported beneﬁts by
evaluating the results of PROSE treatment in ocular cGVHD
patients at the University of Southern California (USC)
Department of Ophthalmology, focusing on changes in visual
function and acuity. These parameters were quantiﬁed using
the Ocular Surface Disease Index (OSDI) survey and Snellen
visual acuity measurements.Figure 1. PROSE device.METHODS
This study was approved by the USC’s institutional review board. Patient
selection criteria for the study included diagnosis with ocular GVHD, referral
to the USC’s department of ophthalmology between November 2009 and
July 2013, and prior failed treatment with aggressive, conventional dry eye
therapy. Visual acuity was measured before and after PROSE treatment, as
was visual function with the validated OSDI survey.
Patients referred for PROSE therapy underwent an optometric consul-
tation to conﬁrm candidacy for treatment. A complete history was obtained
and a thorough eye examination was performed. Patients completed an
OSDI survey to establish baseline visual function before beginning treat-
ment. Various PROSE devices (diameter, toricity, contour, eccentricity) were
tried for each patient. If it was determined that a patient would beneﬁt from
improved comfort, vision, or support of the ocular surface with the devices,
treatment was initiated. PROSE treatment, which encompasses the ﬁtting of
customized scleral devices, has been previously described [14,15]. A follow-
up OSDI survey was administered to patients by telephone after PROSE
ﬁtting was complete. All survey calls were conducted by a trained inter-
viewer not involved in the patient’s care.
Visual Function Survey
The OSDI survey was selected for this study because it has been peer
validated to correlate strongly with the National Eye Institute Visual Func-
tioning Questionnaire and has shown high validity in distinguishing be-
tween normal, mild, moderate, and severe dry eye disease [16]. OSDI
responses result in a numerical score between 0 and 100, from no
discomfort or impairment to the most severe discomfort or impairment.
Patients were directed to answer questions relative to their typical usage of
the device (ie, as though they wore the device all the time, if that were their
norm). During the post-treatment survey, patients were also asked whether
they currently wear their PROSE devices “all,” “most,” “half,” “some,” or
“none” of the time. For those patients not currently wearing their devices,
reasons for terminating use were ascertained.
Visual Acuity
A Snellen scale visual acuity score assessed under each patient’s best
visual setting (ie, spectacles or contact lenses, if applicable) was recorded for
each patient during the initial PROSE consultation and at the completion of
the ﬁtting process. Snellen scores were converted into logarithm of the
minimal angle of resolution (log MAR) acuities for statistical analysis. In the
few cases where applicable, “counting ﬁngers” or “hand motion” acuities
were converted ﬁrst to Snellen equivalents, then to log MAR approxima-
tions, according to published methods [17].
Corneal Staining
Staining was graded on a 1 to 4 scale during initial and follow-up visits
immediately after removal of the PROSE devices. All patients were graded by
the same optometrist for general clinical follow-up. These data were
collected retrospectively and used to assess corneal changes with PROSE
treatment. Staining notations between 2 levels (ie, “1 to 2þ” or “2 to 3þ”)
were averaged and notations of “trace staining” were assigned a rating of .5.
Greatest corneal staining value on each eye was used in our calculations,
regardless of location and extent on the eye. The presence of corneal ﬁla-
ments or epithelial defects was also recorded during these visits. The per-
centage of eyes demonstrating improved staining with treatment was
calculated. The number of eyes with resolved epithelial defects and ﬁla-
mentary keratitis was also recorded.
Statistical Analysis
Changes in OSDI and log MAR visual acuity were compared before and
after PROSE treatment, and statistical signiﬁcance was assessed using Stu-
dent t-test. All statistical analyses were performed with Microsoft Ofﬁce
Excel statistical package.
RESULTS
Of the 41 patients with ocular cGVHD who were screened
for PROSE treatment, 40 were deemed candidates and
completed PROSE treatment. The 1 patient determined to be
a poor PROSE candidate reported no subjective improvement
in ocular comfort with trial devices during initial consulta-
tion. A total of 79 eyes from 40 patients were treated. One eye
from another patient was not treated because of severe
corneal opaciﬁcation. Table 1 shows the most common
treatments that were tried before patients were referred.
Table 1
Treatments Used before PROSE Therapy
Treatment* Value
Artiﬁcial tears 39 (98%)
Topical cyclosporine 37 (93%)
Nightly ointments 34 (85%)
Oral immunosuppressants 32 (80%)
Prednisone 28 (70%)
Tacrolimus 18 (45%)
Sirolimus 12 (30%)
Mycophenolate mofetil 11 (28%)
Cyclosporine 3 (8%)
Dexamethasone 1 (3%)
Punctal plugs 29 (73%)
Topical steroids 29 (73%)
Topical antibiotics 23 (58%)
Bandage contact lenses 10 (25%)
Lacriserts (Aton Pharma, Lawrenceville, NJ) 5 (13%)
Autologous serum tears 5 (13%)
Punctal cauterization 5 (13%)
Data presented are n (%), unless otherwise indicated.
* By patient report at initial consultation.
Table 3
Clinical Results before and after PROSE Treatment
Characteristics Value
OSDI, average  SD
Before PROSE 70.4  21.8*,y
After PROSE 24.2  20.2*,y
Visual acuity, average LogMar
Before PROSE .49* (Snellen w20/60)
After PROSE .16* (Snellen w20/30)
Ocular staining, average
Before PROSE 2.6*
After PROSE .9*
Epithelial defects, n eyes
Before PROSE 9
After PROSE 0
Filamentary keratosis, n eyes
Before PROSE 3
After PROSE 0
* P < .0001.
y Surviving patients only (n ¼ 32).
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complete PROSE treatment was 5.3 (range, 4 to 9). Of the 40
treated patients, 8 (20%) died during our evaluation period
(range, 1 to 40 months). Deceased patients were included in
our visual acuity analysis, but follow-up OSDI surveys could
not be completed in this group. Between the deceased and
surviving patient groups, there was no signiﬁcant difference
in baseline or change in visual acuity. The only signiﬁcant
difference between groups was age: average age among
deceased patients was 64 years compared with 54 years for
survivors. All of the 32 surviving patients (80%) participated
in the follow-up OSDI survey. On average, these surveys were
conducted 12.3 months after ﬁtting completion (range, 1 to
40 months). There was no statistically signiﬁcant difference
in OSDI score changes based on the number of months
elapsed between ﬁtting completion and survey time. Patient
characteristics are summarized in Table 2.
All patients who participated in the follow-up OSDI sur-
vey also reported whether they currently wear their PROSE
devices during waking hours “all,” “most,” “half,” “some,” or
“none” of the time. Patients were instructed to wear the
device throughout the day for optimal results, and the ma-
jority of patients, 29 of 32 (91%), reportedwearing them “all,”
“most,” or “half” of the time. Only 3 patients were no longer
wearing the devices at the time of the follow-up survey. The
reasons cited for terminating use included difﬁculty with
inserting and removing the devices, as well as frustration
with the required cleaning and maintenance to keep the
devices clean.
Overall, patients demonstrated signiﬁcant improvement
in OSDI scores, visual acuity, and clinical ﬁndings after PROSE
treatment. Results are summarized in Table 3.
Of the 29 patients who completed both before and after
surveys and had not discontinued use of their devices at the
time of follow-up, 28 had improved OSDI scores. OSDI scoresTable 2
Patient Characteristics
Characteristic Surviving Deceased Total
Patients, n 32 8 40
Eyes, n 63 16 79
Age, average, yr 54.1 64.1 56.1
Male/female, n 21/11 7/1 28/12among these 29 patients improved an average of 70.9%,
decreasing from a before treatment OSDI score of 72.6 20.1
to a follow-up OSDI of 21.1 14.9 (P < .0001). The 3 patients
who were no longer wearing their devices averaged an 8%
increase (worsening) in OSDI scores because of nonrespon-
sive symptoms, such as light sensitivity, grittiness, soreness,
and discomfort in dry environments.
Of the 79 eyes ﬁtted, 71 (90%) showed improved visual
acuity from the pre-ﬁtting consultation. Fourteen eyes (18%)
showed 1-line improvement and 57 eyes (72%) showed 2- or
greater lines of improvement. Five eyes (6%) showed no
change in visual acuity (these remained at either 20/20, hand
motion, or counting ﬁngers), whereas 3 eyes (4%) showed
decline in visual acuity (all changed from 20/20 to 20/25). On
average, log MAR values improved from .49  .52 to .16  .44
(P< .0001, n¼ 40 patients) after PROSE. This improvement is
comparable to a Snellen score change of approximately 20/
60 to 20/30.
Corneal staining data showed improved ocular surfaces in
a majority of eyes after treatment. Sixty-six of 79 eyes (84%)
had decreased staining, 9 (11%) showed no change, and 4
(5%) had increased corneal staining. The average change was
from 2.5  1.03 before treatment to 1  1.05 after treatment
(P< .0001, n¼ 79 eyes). Before ﬁtting, 9 eyes had ﬁlamentary
keratitis and 3 eyes had epithelial defects. All of these had
resolved by ﬁtting completion.
DISCUSSION
Ocular GVHD can signiﬁcantly limit a cancer survivor’s
quality of life. Visual changes and ocular discomfort can
affect a patient’s ability to maintain employment, perform
routine household tasks, and enjoy normal activities.
Prior studies on scleral lens treatment have suggested
their efﬁcacy in treating GVHD patients. In a cohort of 5
patients, Schornack et al. reported improved visual acuity in
7 of 10 eyes ﬁtted with scleral lenses for patients with ker-
atoconjuncivitis sicca associated with cGVHD [8]. Takahide
et al. used the OSDI survey in 9 GVHD patients, who showed
an average OSDI improvement of 69 points after scleral lens
treatment, which is in line with our average OSDI improve-
ment of 52 points [9]. Our study isolates a large cohort of
GVHD patients and corroborates OSDI improvements with
visual acuity improvements in the same patients.
We report signiﬁcantly reduced morbidity in ocular
GVHD patients who successfully undergo PROSE therapy.
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supports the clinical beneﬁts of PROSE treatment in ocular
GVHD patients. Improved ocular comfort was widespread,
as 97% of patients (28 of 29) still wearing their PROSE de-
vices showed improved OSDI scores after treatment. Visual
acuity changes were similarly positive with 90% of eyes (71
of 79) showing improvement with treatment; the average
change from approximately 20/60 to 20/30 is clinically
signiﬁcant. Eight-four percent of eyes (66 of 79) showed
decreased corneal staining and all patients presenting with
epithelial defects or ﬁlamentary keratitis showed resolution
of these conditions after treatment. Figure 2 exempliﬁes the
ocular surface improvements that can be seen in GVHD
patients with PROSE treatment. Furthermore, although our
study did not quantify the time course of relief, our clinic’s
experience is that symptoms improve quickly with PROSE
treatmentdeven immediately upon initial ﬁtting in some
cases. Overall, these results suggest that PROSE therapy is
very effective in relieving dry eye symptoms secondary to
cGVHD.
In our clinic, PROSE treatment is considered when pa-
tients have not had success with traditional ﬁrst-line thera-
pies, such as artiﬁcial tears, topical steroids or cyclosporine,
punctal plugs, or ointments. In this study, almost all patients
had previously used topical cyclosporine or artiﬁcial tears
before PROSE ﬁtting. Nearly all of our patients received
topical or systemic steroid therapy before referral for PROSE
evaluation. The few who did not receive steroids had been
treated by physicians wary of topical steroid use in ocular
GVHD patients with severe surface compromise.
Frequent challenges among patients during PROSE treat-
ment included the precision required for application and
removal and daily maintenance of the devices. Of the pa-
tients ﬁtted during our evaluation period, 3 terminated use
because of difﬁculty with application and removal or because
of what they perceived as “burdensome upkeep.” Addition-
ally, 4 patients (all over 65 years old) required caretaker
assistance to handle the devices; these caretakers were
trained in proper application, removal, and usage, alongsideFigure 2. Anterior segment photos taken by referring physician at initial consultation
initiation of PROSE treatment, with epithelial surfaces intact (bottom row).the patient. Patients also reported intermittent mucus build-
up over the lens surface throughout the day, which required
additional cleaning to maintain optimal comfort and vision.
For most patients, these challenges were minimal compared
with the symptomatic relief the treatment offered. However,
clinicians should still carefully consider factors such as pa-
tient motivation, ability to follow physician instructions,
mobility, degree of systemic disease, and access to necessary
caretakers to distinguish appropriate candidates for PROSE
treatment. Ultimately, frequent and proper usage of the de-
vice are fundamental to ensuring that patients receive ex-
pected beneﬁts.
There were also a few limitations to this study. Primarily,
the population was relatively homogenous: 93% of patients
in the study were Caucasian, 70%were ages 50 to 70, and 70%
were male. This homogeneity made it difﬁcult to assess dif-
ferences in patient experience by ethnicity, age, or gender.
Additionally, the study was retrospective in nature, which
may have contributed to hindsight bias. Still, the study is
strengthened by the percentage of patients reached for
post-treatment follow-up. All surviving patients were
administered a post-treatment OSDI survey, giving an overall
follow-up rate of 80%, when taking into account deceased
patients. Finally, although the corneal staining data were
assessed by the same practitioner for all patients, a peer-
validated grading scale was not used. Although the clinical
scale used in our study could reliably identify whether pa-
tients had improved or worsened, in future studies, we
would consider using the an established scale, such as the
Oxford schema, which utilizes a standard chart of stain
patterns to quantify epithelial damage, to more accurately
determine the magnitude of this change.
Our results indicate that PROSE therapy, utilizing
customized scleral lenses, can be used tomanage debilitating
ocular symptoms in patients with ocular GVHD. PROSE
treatment can improve visual function, visual acuity, and
ocular surface presentation, and should be considered for
appropriate candidates who have not responded sufﬁciently
to other treatment modalities., demonstrating large bilateral epithelial defects (top row) and 3 months after
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